Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
Published February 2, 2022 · Recall initiated: December 29, 2021
Summary
FDA records drug Class II recall D-0450-2022, published February 2, 2022 and initiated December 29, 2021. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 792 bottles; Lot: Batch # PF4520028B & PF4520028A, Exp. Date 11/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Superpotent and Failed Tablet/Capsule Specifications
What to do
Voluntary: Firm initiated · Letter
Get an email if PIOGLITAZONE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- PIOGLITAZONE
- Manufacturer
- Aurobindo Pharma USA Inc.
- Distributor
- Nationwide in the US
- UPC
- 0357237221303
- Lot
- Batch # PF4520028B & PF4520028A, Exp. Date 11/2022
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDATrypan Blue 0.03%, 0.5mL per syringe, Sterile Ophthalmic Solution for Injection Preservative Free, Single UseFebruary 2, 2022
- FDAMetoprolol Succinate Extended-Release Tablets, USP 50 mg, 500-count bottle, Rx Only, Manufactured by: AlkemFebruary 2, 2022
- FDAVancomycin HCl Oral Solution (PF) 125mg / 2.5mL (50 mg/mL), 2.5 mL per syringe, Single Dose Syringe for OralFebruary 2, 2022
- FDAProctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) topical aerosol, 10 g aerosolFebruary 2, 2022
- FDATetracaine HCl Nasal Solution, 4%, 240 mL per bottle, Multiple Dose Container for Intranasal Use, Edge Pharma,February 2, 2022
- FDACariFree CTx4 GEl 5000 1.1% Neutral Sodium Fluoride Mint, 2 oz (57 g) Rx only NDC: 61578-205-01 ManufacturedFebruary 2, 2022
Questions about this recall
Was Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05 recalled?
Yes. FDA published recall D-0450-2022 on February 2, 2022. Reported hazard: Superpotent and Failed Tablet/Capsule Specifications
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: PIOGLITAZONE. UPC: 0357237221303.